Novo Nordisk shares jumped 8% Monday after Hims & Hers stated it’ll pull its copycat weight-loss capsule off the market.
Novo Nordisk, maker of Wegovy, and the U.S. Meals and Drug Administration had threatened authorized motion in opposition to telehealth agency Hims & Hers, which introduced over the weekend it might not promote a knockoff Wegovy capsule for as little as $49, roughly $100 lower than what Novo sells the branded capsule for on its direct-to-consumer platform NovoCare.
“Since launching the compounded semaglutide capsule on our platform, we have had constructive conversations with stakeholders throughout the trade,” Hims & Hers posted on social media on Saturday. “Because of this, we’ve got determined to cease providing entry to this remedy. We stay dedicated to the hundreds of thousands of People who depend upon us for entry to secure, reasonably priced, and customized care.”
The information of the $49 Wegovy copy led each Novo and chief rival Eli Lilly shares to tank on Thursday. Hims, in the meantime, soared on the information to later pare beneficial properties when Novo threatened authorized motion.
In early Monday buying and selling, Novo shares have been up 8.1%, however the inventory remains to be down almost 50% over the previous 12 months. In the meantime, Hims fell 15.3% in premarket buying and selling, and Lilly shares have been 1.4% increased.
Novo Nordisk inventory has fallen over the previous yr, partly as a consequence of aggressive strain from companies like Eli Lilly and Hims & Hers.
Hims has profited vastly from promoting so-called compounded variations of injectable semaglutide beneath a regulatory loophole that permits different firms to promote copycats of the medicine if the branded medicines are in brief provide.
Novo’s bestselling semaglutide — the lively ingredient in Wegovy and Ozempic — has beforehand confronted shortages each within the U.S. and in Europe, as demand far outstripped provide within the early days of the GLP-1 growth. Since then, Novo has ramped up manufacturing capabilities, together with by shopping for fill-finish producer Catalent for $16.5 billion, and it has resolved any provide restraints.
No shortages have been reported for the capsule, which launched in January this yr.
On Friday, the FDA stated it supposed to take “decisive steps” to limit such practises by compounding pharmacies, together with Hims. “These actions are aimed to safeguard customers from medicine for which the FDA can not confirm high quality, security, or efficacy,” the regulator stated in a press release.
Hims’ semaglutide is not FDA-approved, and the FDA additionally stated it might crack down on “deceptive direct-to-consumer promoting.”
“In promotional supplies, firms can not declare that non-FDA-approved compounded merchandise are generic variations or the identical as medicine accepted by FDA,” it stated.
Novo has repeatedly cited a difficult U.S. market, together with compounding, as a motive for slowing gross sales. In 2026, Novo expects to see each income and earnings declining by between 5% and 13%.
On Thursday, Novo stated it might take authorized motion in opposition to Hims.
“The motion by Hims & Hers is illegitimate mass compounding that poses a major threat to affected person security,” the corporate stated in a press release. “That is one other instance of Hims & Hers’ historic behaviour of duping the American public with knock-off GLP-1 merchandise, and the FDA has beforehand warned them about their misleading promoting of GLP-1 knock-offs.”
— CNBC’s Laya Neelakandan contributed to this story
